hotspot -WSS

hotspot

author：Wikipedia 2025-09-27 19:37:52 - browse：82

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Medicare to cover more brain scans for Alzheimer’s patients

focus

WSS

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Resistance to opioid

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Custom gene therapy hints at new path for rare disease treatments

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

FDA approves RSV monoclonal antibody for infants, toddlers

knowledge

hotspot

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

STAT Boddities: What happens to the brain when we get scared?

Alkermes shareholders re

Key House panel plots a new health care package

How to save PrEP access — and even expand it

At Orexo, a ‘turning point’ for everything but digital health

What does generative AI mean for health care? We asked experts

Doctors on social media are being harassed and cyberbullied

DIEP, the 'gold standard' of breast reconstruction, is under threat

Medicare to cover more brain scans for Alzheimer’s patients

focus

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Why don't Americans have at

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

At Orexo, a ‘turning point’ for everything but digital health

How dance can help nurses traumatized by Covid

Resistance to opioid

focus

focus

focus

entertainment